Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
MedImmune and 2 cancer institutes team up for drug R&D
MedImmune is partnering with the Ludwig Institute for Cancer Research and the Cancer Research Institute to evaluate combinations of cancer immunotherapies in clinical trials. Among treatments to be tested are MedImmune's monoclonal antibody drug candidates tremelimumab, anti-OX40 and MED14736. The trials will be carried out by the cancer institutes.
Or we can send an email on your behalf